Myeloma Genomics and cell signaling

P-333: Multi-omic analysis of multiple myeloma subtypes reveals epigenetic programs of high-risk disease

P-335: Small nucleotide, copy number and structural variants cooperate to hijack driver genes in extramedullary progression of myeloma

P-336: Prognostic relevance of NOTCH-driven matrisome-associated genes in multiple myeloma

P-337: The germinal center origin and progression of MM is captured by 83 Vk*MYC MM transplantable lines that share overlapping genomic diversity with human disease

P-338: Differential DNA Mutation Profiles in Multiple Myeloma Patients: Implications of PET/CT Findings

P-341: Use of Optical Genome Mapping in the Cytogenetic Diagnosis of Multiple Myeloma

P-342: Genomic Profiling of Treated High-Risk Smoldering Multiple Myeloma

P-343: Evaluation of single nucleotide variants in BRCA1, CDKN1A, TP53BP, and XRCC1 in multiple myeloma patients undergoing hematopoietic stem cell transplantation. Association with clinical outcomes

P-344: Multiomics profiling of extramedullary multiple myeloma tumors and their microenvironment

P-345: Connecting 1q amplification and PHF19 expression in high-risk myeloma clones

P-346: Internal Tandem Duplications of the BCMA Transmembrane Domain are Common in Hyperdiploid Multiple Myeloma and Associated with Constitutive NF-kB Signaling

P-347: Longitudinal Profiling Identifies Genetic Mechanisms of Resistance to Four Different Drug Classes in a t(4;14) Positive Patient

P-348: ADAR1-regulated cytoplasmic dsRNA-immune sensing pathway is a novel mechanism of lenalidomide resistance in multiple myeloma

P-349: A retrospective assessment of biologically relevant genomic perturbations and variants of unknown significance in a cohort of plasma cell disorder at our institution; a single center experience

P-350: Single cell Analysis identifies new insights into the development of venetoclax resistant in Multiple Myeloma patients

P-351: Are genomic lesions of Cereblon pathway genes sufficient to explain clinical relapses from IMiD-based treatment in multiple myeloma (MM)?

P-352: Enhanced expression of DNp73 promotes drug resistance and immune evasion in multiple myeloma by targeting the MYC and MYCN pathways

P-353: In vitro functional characterization of a multiple myeloma
susceptibility locus

P-354: Whole genome sequencing reveals significant genetic admixture in multiple myeloma patients, impacting assessment of etiology

P-355: A novel genomewide RNA-Targeting CRISPR/Cas13 Screen Identifies a Plasma Cell-Specific long non-coding RNA (LncRNA) Essential for Myeloma Cell Growth

P-356: EFFECT OF AMPLIFICATION OR GAIN OF 1Q21 IN PATIENTS WITH MULTIPLE MYELOMA TREATED WITH DARATUMUMAB

P-357: Individualized Risk in Newly Diagnosed Multiple Myeloma

P-360: Exploring the role of the Polycomb Repressive Complex 2 in High-Risk Multiple Myeloma

P-361: Genomic and transcriptomic landscape of hyper-APOBEC multiple myeloma

P-362: ID2 acts as a novel tumor suppressor in MM by inhibition of TCF3 transcriptional activity

P-363: Mitochondrial Protease ClpP is a Novel Immunogenic Vulnerability in Multiple Myeloma

P-371: Mutant-specific pharmacological inhibition of KRAS in multiple myeloma and functional genomics studies to identify mechanisms regulating myeloma cell response vs. resistance to KRAS inhibition.

P-373: Functional genomics of genes residing in the minimally deleted chromosome 17p13 region in multiple myeloma: therapeutic implications

P-376: Genomic and transcriptional profiling stratifies myeloma models into two clusters with distinct risk signatures and drug responses